Literature DB >> 23335540

The cost of cytoreductive surgery and perioperative intraperitoneal chemotherapy in the treatment of peritoneal malignancy in one Greek institute.

A A Tentes1, N Pallas, O Korakianitis, C Mavroudis, A Spiridonidou, G Zorbas, S Popidis, N Papadoniou, V Darladima, A Smyrnis, C Siopis.   

Abstract

PURPOSE: Cytoreductive surgery and perioperative intraperitoneal chemotherapy in the treatment of patients with peritoneal malignancy is expensive. The purpose of this study was to estimate the current cost of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy and identify the most significant related parameters in one center in Greece.
METHODS: A retrospective economic study was carried out on 105 patients that underwent 108 cytoreductive operations and hyperthermic intraoperative peritoneal chemotherapy (HIPEC) from 2006-2011 for peritoneal malignancy. The economic cost included the daily cost of hospital bed occupancy, the daily cost of occupancy in the intensive care unit (ICU), the expenditures (materials and drugs), and the preoperative, intraoperative, and postoperative examinations.
RESULTS: The mean length of stay in the ICU and the mean hospitalization time was 5 and 23 days, respectively. The hospital mortality and morbidity was 5.6% (6 patients) and 48.17percnt; respectively. The mean cost of treatment was 15677.3±11910.6 euros (range=4258,47-95990,87) per patient. Morbidity (p=0.009), and prolonged stay in the ICU (p<0.001) were the parameters that influenced independently the cost of treatment.
CONCLUSION: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy is an expensive treatment. The economic cost is largely influenced by morbidity and the length of stay in the ICU.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23335540

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  4 in total

1.  Fear of Cancer Recurrence in peritoneal malignancy patients following treatment: a cross-sectional study.

Authors:  Rayan Taher; Norman John Carr; Nancy Vanderpuye; Sophia Stanford
Journal:  J Cancer Surviv       Date:  2022-07-28       Impact factor: 4.062

2.  Cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) versus standard of care (SoC) in people with peritoneal metastases from colorectal, ovarian or gastric origin: protocol for a systematic review and individual participant data (IPD) meta-analyses of effectiveness and cost-effectiveness.

Authors:  Kurinchi Gurusamy; Claire L Vale; Elena Pizzo; R Bhanot; Brian R Davidson; Tim Mould; Muntzer Mughal; Mark Saunders; Omer Aziz; Sarah O'Dwyer
Journal:  BMJ Open       Date:  2020-05-12       Impact factor: 2.692

3.  Impact of cumulative complications on 1-year treatment-related healthcare costs in patients with colorectal peritoneal metastases undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Authors:  Femke A van der Zant; Bob J L Kooijman; Judith E K R Hentzen; Wijnand Helfrich; Emily M Ploeg; Robert J van Ginkel; Barbara L van Leeuwen; Lukas B Been; Joost M Klaase; Patrick H J Hemmer; Christian S van der Hilst; Schelto Kruijff
Journal:  BJS Open       Date:  2022-09-02

4.  Impact of extent of disease on 1-year healthcare costs in patients who undergo cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: retrospective observational cohort study.

Authors:  B J L Kooijman; J E K R Hentzen; C S van der Hilst; L B Been; R J van Ginkel; P H J Hemmer; J M Klaase; S Kruijff
Journal:  BJS Open       Date:  2020-07-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.